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Purpose. Review the safety and long-term success with portosystemic shunts in children at a single institution. Methods.A n
IRB-approved, retrospective chart review of all children ages 19 and undergoing surgical portosystemic shunt from January
1990– September 2008. Results. Ten patients were identiﬁed, 8 females and 2 males, with a mean age of 15 years (range 5–
19 years). Primary diagnoses were congenital hepatic ﬁbrosis (5), hepatic vein thrombosis (2), portal vein thrombosis (2), and
cystic ﬁbrosis (1). Primary indications were repeated variceal bleeding (6), symptomatic hypersplenism (2), and signiﬁcant
liver dysfunction (2). Procedures performed were distal splenorenal bypass (4), side-to-side portocaval shunt (3), proximal
splenorenal shunt (2), and an interposition H-graft portocaval shunt (1). There was no perioperative mortality and only minor
morbidity. Seventy percent of patients had improvement of their symptoms. Eighty percent of shunts remained patent. Two were
occluded at a median follow-up of 50 months (range 0.5–13.16 years). Two patients underwent subsequent liver transplantation.
Two patients died at 0.5 and 12.8 years postoperatively, one from multisystem failure with cystic ﬁbrosis and one from post-
operative transplant complications. Conclusions. The need for portosystemic shunts in children is rare. However, in the era
of liver transplantation, portosystemic shunts in selected patients with well-preserved liver function remains important. We
conclude that portosystemic shunts are safe and eﬃcacious in the control of variceal hemorrhage and symptoms related to
hypersplenism.
1.Introduction
The approach to portal hypertension (PH) in children
has evolved signiﬁcantly over the past half-century. With
improved endoscopic treatments for variceal bleeding, liver
transplantation and transjugular intrahepatic portosystemic
shunts (TIPSs) , the use of portal systemic shunts (PSSs)
has been relegated to a few selected patients in the pediatric
population. However, our experience and the experience of
others [1–7] continue to support the valuable role of PSSs in
selected children.
PH in children can be divided into two main categories:
(i) extrahepatic portal hypertension (EHPH) and (ii) intra-
hepatic portal hypertension (IHPH). EHPH in children is
commonly due to main portal vein thrombosis, which may
variably extend into the splenic, mesenteric, or intrahepatic
portal veins. In the setting of EHPH, liver function is
typically preserved. Consequently, hepatic decompensation
is rare and liver transplantation is seldom indicated. In
contrast, in patients with IHPH, hepatic decompensation
often occurs over time as evident clinically by ascites,
coagulopathy, and encephalopathy. IHPH in children can
result from a number of distinct causes including congenital
hepatic ﬁbrosis, hepatic vein thrombosis, inborn errors of
metabolism, biliary atresia, and cystic ﬁbrosis.
Esophagogastricvaricealhemorrhage,splenomegaly,and
hypersplenism are the common clinical manifestations of
both EHPH and IHPH. Historically, repeated variceal
hemorrhage has been the primary indication for PSSs in
children[7,8].AlthoughPSSshaveclearlyproveneﬃcacious
in controlling variceal hemorrhage, persistent concerns
regarding variable degrees of hepatic encephalopathy and its
eﬀects have persisted [2, 9] .Y e tr e c e n tr e p o r t so fP S S sh a v e
not substantiated those outcomes [3, 5]. Indeed, patients2 HPB Surgery
with patent grafts have had good long-term health and no
decrease in scholastic performance related to occult portal-
systemic encephalopathy (PSE) [1, 3, 5, 10].
Our study aims to further assess the outcomes of PSSs
in children to determine whether PSSs in patients with
EHPH or IHPH are clinically valuable in the era of liver
transplantation.
2. Methods
2.1. Patient Selection. This study was approved by the IRB
at the Mayo Clinic, Rochester. Ten pediatric patients who
underwentPSSswereidentiﬁedretrospectivelybetween1990
and2008throughourcomputerdatabase.Allpatientsduring
this time period were included in this report regardless of the
causes leading to surgical PSSs.
There were 8 females and 2 males with a mean age of
15 years (range 5–19 years). Patients were followed for 6
months to 13 years with a median followup of 50 months.
Our electronic database was examined for preoperative and
postoperative (1) demographic ﬁndings, (2) liver and renal
functions, (3) serum ammonia levels, (4) ascites, (5) type
of shunt performed, (6) primary and secondary diseases
leading to portal hypertension, (7) indication for surgical
PSS, (8) 30-day operative mortality, (9) shunt patency, (10)
intra-operativecomplications,(11)patientsurvival,and(12)
subsequent need for liver transplantation (Table 1). Model
for End-stage Liver Disease (MELD) scores were calculated
using serum creatinine (mg/dL), bilirubin (mg/dL) and INR
values collected just before surgery and at various times
postoperatively. The MELD score is calculated using the
following formula: MELD = (0.957 × loge (serum creatinine
mg/dL) + 0.378 × loge (serum bilirubin mg/dL) + 1.120
× loge (INR) + 0.643) 10. All MELD scores were rounded
to the nearest whole number. If a patient received two or
more dialysis treatments within a given week where scores
were generated, then serum creatinine levels were set at
4mg/dL.
Primary indications for PSSs were repeated variceal
bleeding despite endoscopic therapy (6), symptomatic
hypersplenism with thrombocytopenia (2), and liver dys-
function in the setting of hepatic vein thrombosis (2).
Evaluationofportal hypertensionwasconductedbyDoppler
ultrasonography of the portal venous system and hepatic
veins. In addition, endoscopic evaluation of esophageal and
gastric varices was conducted on all patients preoperatively.
Liver biopsies were performed on patients with ﬁbrotic
liver disease. All patients undergoing PSSs had pre- and
postoperative liver and renal functions testing. Selected
patients had MR venography of the portal venous system,
renal veins, and IVC to assess the degree of patency. Visceral
arteriogramandhepaticvenogramswerealsousedselectively
to evaluate patency and size of abdominal vasculature.
2.2. Surgical Techniques. PSSs performed were distal sp-
lenorenal bypass in 4, side-to-side portocaval shunt in 3,
proximal splenorenal shunt in 2, and a portocaval H-graft
using a spiral vein graft in one patient (Figure 1).
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Figure 1: The four types of shunts used in our series. PV: portal
vein; CV: cardiac vein; SV: splenic vein; IMV: inferior mesenteric
vein; LRV: left renal vein; SMV: superior mesenteric vein; IVC:
inferior vena cava; SGV: short gastric veins.
3. Results
Primary diagnoses were congenital hepatic ﬁbrosis (5),
hepatic vein thrombosis (2), portal vein thrombosis (2),
a n dc y s t i cﬁ b r o s i s( 1 )( Table 1). Patients in this study
were grouped into two categories based on the causes of
their portal hypertension (Table 1). Those patients with
portal vein thrombosis were categorized as EHPH, and all
other patients with congenital hepatic ﬁbrosis, hepatic vein
thrombosis, and cystic ﬁbrosis with subsequent ﬁbrotic liver
disease were categorized as IHPH. Only three patients with
IHPH had liver dysfunction as evident by an elevated MELD
score.
Six patients underwent PSSs for repeated variceal bleed-
ing despite endoscopic therapy. Both patients with portal
vein thrombosis had variceal bleeding as the primary
indication for PSSs. One of these patients is alive and well
7 years after a DSRS, which remains patent. The otherHPB Surgery 3
Table 1: Ten patients were identiﬁed in the study. They are listed from 1 to 10 and referenced this way throughout the paper. DSRS: distal
splenorenal shunt; PSRS: proximal splenorenal shunt; PCS: portocaval shunt; PV: portal vein; UTI: urinary tract infection. ∗MELD score 1
month post shunt. ∗∗MELD score 1 month and 13 years post shunt.
Patient
no. Age Primary
disease Shunt type
MELD/PELD
score pre-
and postop
Primary reason
for shunt Complications 30-day
mortality
Graft
patency
Followup
years
EHPH group
11 7 PV
Thrombosis DSRS Variceal
Bleeding None None Patent 7.08 Alive
21 7 PV
Thrombosis PSRS Variceal
Bleeding None None Thrombosed 1.08 Alive
IHPH group
31 7
Congenital
Hepatic
Fibrosis
DSRS 6 6 Variceal
Bleeding None None Patent 7.4 Alive
45
Congenital
Hepatic
Fibrosis
Side-to-side
PCS 78Variceal
Bleeding
UTI,
central-line
infection
None Patent 0.92 Alive
51 9 Cystic
Fibrosis DSRS 7 11 Variceal
Bleeding None None Patent 0.5 Died
61 5
Congenital
Hepatic
Fibrosis
PSRS 20 21 Variceal
Bleeding
Bleeding
Fundal Varices
10 days postop
Negative
reexploration
Received
liver
transplant 13
months later
post PSS
1.08 Alive
71 8 Hepatic Vein
Thrombosis
Side-to-side
PCS 18 12∗ Liver
Dysfunction None None
Shunt
occluded at 3
months.
Received
liver txp 6
months later
12.8 Died
81 8 Hepatic Vein
Thrombosis PCSH-graft 18 13∗∗ Liver
Dysfunction None None Patent 13.16 Alive
91 5
Congenital
Hepatic
Fibrosis
DSRS 7 7 Hypersplenism None None Patent 6.5 Alive
10 10
Congenital
Hepatic
Fibrosis
Side-to-side
PCS 8 11 Hypersplenism None None Patent 1.92 Alive
patient, who had an orthotopic liver transplant as an infant,
developed a portal vein thrombosis, which was complicated
by variceal bleeding 14 years after liver transplantation. The
PSRS thrombosed one year postoperatively and that patient
is under evaluation for revisional PSS.
The remaining 4 patients with variceal bleeding as the
main reason for PSSs had primary diagnoses of congenital
ﬁbrosis (3) and cystic ﬁbrosis (1). Two patients with congen-
ital hepatic ﬁbrosis are alive and well with patent shunts at
7.4 and 1 years postoperatively. The remaining patient with
congenital hepatic ﬁbrosis, who had signiﬁcant preoperative
liver dysfunction (MELD = 20), had an early postoperative
variceal hemorrhage after PSS. Repeat operation failed to
conﬁrm shunt thrombosis. Despite nonexistence of further
variceal hemorrhage, the patient underwent liver transplan-
tation13monthslaterandshuntpatencywasconﬁrmed.The
patient with cystic ﬁbrosis died with a patent shunt 6 months
aftershuntingduetomultisystemfailureasacomplicationof
cystic ﬁbrosis.
Two patients underwent PSSs due to signiﬁcant liver
dysfunction resulting from hepatic venous thrombosis. One
patient who underwent a side-to-side portocaval shunt had
progression of the hepatic venous thrombosis to include
thrombosis of the retrohepatic IVC and thrombosis of the
shunt three months postoperatively. This patient underwent
liver transplantation but died 12 years later from hepatorenal
failure awaiting a second liver transplantation. The other
patient with hepatic vein thrombosis and signiﬁcant liver
dysfunction received a portocaval H-graft shunt using a
spiral vein graft. This patient is alive and well 13 years
postoperatively with a patent shunt.
The ﬁnal two patients with IHPH underwent PSSs for
symptomatic hypersplenism, which included symptomatic
splenomegaly and thrombocytopenia. The ﬁrst patient4 HPB Surgery
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Figure 2: MELD/PELD scores of the patients with signiﬁcant liver
dysfunction. Signiﬁcant liver dysfunction in this study was set at a
MELD/PELD score of 15. Three patients (patients 4, 6, and 10) had
signiﬁcant liver dysfunction before shunt. Two of the three patients
saw a signiﬁcant improvement in liver function post shunt.
Table 2: Survey of PSE symptoms along with ammonia levels pre
and post PSS.
Patient Ammonia Pre/Post PSS µmol/liter PSE Symptoms
1 59 114 None
22 0 1 6 N o n e
31 9 3 1 P r e s e n t
4 132 113 Present
65 9 6 8 P r e s e n t
81 3 3 0 N o n e
91 8 2 1 P r e s e n t
10 11 30 None
underwent a DSRS. One patient that underwent DSRS sus-
tained a signiﬁcant reduction in splenomegaly and normal-
ization ofhis plateletcountand hasconﬁrmedshunt patency
8yearspostoperatively.Thesecondpatientunderwentaside-
to-side portocaval shunt and also sustained a similar reduc-
tion in splenomegaly and normalization of leukocyte count
along with a partial correction of his thrombocytopenia (63–
86 × 109 platelets per liter). This patient has a conﬁrmed
patentshunt2yearspostoperatively.Therefore,bothpatients
with symptomatic hypersplenism received signiﬁcant long-
term relief of their symptoms following their shunt proce-
dures and neither patient required a splenectomy.
In our practice we performed 10 open PSSs in the time
period listed. Three of these patients had liver dysfunction
as measured by their MELD scores. However, 2 of these
3 patients received a signiﬁcant improvement in their liver
function following their shunt procedure and one of these
patients has been able to maintain this improvement at long-
term followup (13 years) (Figure 2).
To assess for potential PSE after PSSs, the followup
recordsandquestionnaireswereexaminedin8of10patients.
Two patients were excluded because they lacked speciﬁc
followup regarding PSE (patients number 5 and 7). Four
patients noted an increase in fatigue and a decrease in
scholasticperformanceandorshort-termmemory(Table 2).
There was no association between PSE and serum ammonia
levels.
4. Discussion
Our ﬁndings conﬁrm the safety and eﬃcacy of elective PSS
inselectedchildrenforcomplicationsofportalhypertension.
Although our experience was small, this data supports simi-
lar reports from others [1–7]. PSSs provided durable control
of variceal hemorrhage and symptomatic hypersplenism and
was not associated with rapid deterioration of liver function
or clinical encephalopathy. These ﬁndings suggest that PSSs
should remain a treatment option for the complications of
portal hypertension in selected children in the era of liver
transplantation.
Multiple previous publications about PSSs in children
or involving children have shown PSSs to be safe and
eﬀective with excellent long-term patency rates. There
were no operative deaths in our series and operative and
perioperative complications were limited. The patency
rate of 80% in our patients is similar to that of others
[3, 5, 7] and led to durable relief of the portal hypertensive
indications for operation. Admittedly PSSs in our patients
were performed both selectively and electively. PSS was
performed infrequently over the period of study, which
reﬂects the general trend for PSSs nationally. Although
three of our patients had impaired liver function, selection
of children for PSSs was based on failure of medical
intervention and preserved liver function. In fact, two of our
patients had EHPH and those with IHPH had underlying
hepatopathies in which liver function is typically maintained
over many years. All PSSs herein were performed electively.
We did not encounter any patient who required emergent
PSS for persistent variceal hemorrhage. This ﬁnding likely
resulted from improved management of patients with acute
variceal hemorrhage pharmacologically, endoscopically, and
intravascularly and the location of our referral practice.
Selection of PSSs was dependent anatomically upon the
degree of patency of the portal venous system, size of the
portal venous branch for shunting, and underlying liver
function. Selection of PSSs in children was also aﬀected by
thegoalsofmaintainingsplenicfunctionandminimizingthe
risk of encephalopathy or learning disorders. Preoperative
imaging was performed to assess the degree of patency
of the portal venous system and the absolute size of the
major portal venous tributaries, which were relevant to
the construction of the portosystemic venous anastomo-
sis. Although portal venography was used in our early
experience, dimensional imaging with contrast-enhanced
computed tomography or magnetic resonance imaging with
vascular reconstruction is now preferred because they accu-
rately depict venous size and spatial relationships of the veins
within the abdomen and the extent of thrombosis if present.
In general, portal venous branch size of nearly 1cm was
preferred for elective PSS to reduce the likelihood of shunt
thrombosis. Selective PSSs were preferred in patients with
underlying chronic liver disease to maintain liver perfusion.
Many of the treatment options for symptomatic hyper-
splenism in the setting IHPH presented in the literature
for patients with well-preserved liver function involve some
type of splenorenal shunt and splenectomy [4, 6, 7]. In
the pediatric patient population, where long-term survivalHPB Surgery 5
is often anticipated, a splenectomy comes with signiﬁcant
risks and problems making preservation of the spleen highly
desirable [4, 6]. In our series spleen sparing central PSS was
preferred to reduce the risk of postsplenectomy sepsis, which
resulted in durable patent shunts and long-term cessation of
preoperative symptoms.
In our patients with hepatic venous outﬂow obstruction
(HVOO), central or nonselective PSSs were used to decom-
press the liver. Notably central PSSs for HVOO are often
associated with durable improvement in liver function with
relief of hepatic congestion [5, 7, 8]. Liver transplantation
was clearly an alternative treatment for our patients with
HVOO. Indeed, TIPS as a bridge to liver transplantation
was certainly an emergent option for all patients with IHPH
who were acutely bleeding, but such treatment was not
required. TIPS has been performed successfully for patients
with HVOO in a number of series, however, with low short-
term patency rates ranging from 12%–60% necessitating
additional interventions [11–13]. One patient in our series
with HVOO was able to maintain the signiﬁcant improve-
ments in liver function achieved with the surgical PSS and
has avoided the need for subsequent liver transplantation for
13 years with a patent shunt. This type of long-term patency
is rarely achieved with the TIPS procedure in patients with
HVOO [11–15].
Choice of PSS for EHPH was primarily dependent upon
the extent of the portal venous thrombosis. Although the
term“portalvenousthrombosis”isusedtodenoteanyextent
of thrombosis involving the portal venous system, deﬁning
the site and extent of thrombosis is essential to determine
whether a PSS can be undertaken and which PSS can be con-
structed.WehavelimitedPSSstopatientswiththrombosisof
the main portal vein with or without intrahepatic extension
with patency of the superior mesenteric and splenic vein
conﬂuence. Isolated superior mesenteric vein patency does
permit mesocaval shunting for variceal hemorrhage though
concurrent splenectomy would be required for symptomatic
hypersplenism. Isolated splenic vein thrombosis was not
encountered though distal splenorenal shunting remains
an option for such patients. We have had no experience
with the “Rex Shunt”, which eﬀectively is a portoportal or
mesentericoportal venous bypass of an isolated segmental
thrombosis of the main portal vein. Few publications
exist regarding outcomes using the Rex Shunt; however,
opponents of this shunt argue that it is associated with
increased complications including decreased patency rates
and an increased need for revisions [3]. Proponents of
the Rex Shunt suggest that this shunt is more physiologic,
is associated with decreased PSE, and improved somatic
growth [16–19]. These same proponents suggest that the
diﬀerences in complication rates between the Rex Shunt
and other types of shunts, selective or non-selective, are
associated with technique rather than the intrinsic factors of
the shunt.
There are potential long-term complications that have
been reported in patients with PSSs. The most signiﬁcant
of these complications include shunt thrombosis, an increase
risk of surgery during subsequent liver transplant, and PSE.
Shunt thrombosis occurred in 2 patients (1 EHPH and 1
IHPH) in our series. The IHPH patient with a thrombosed
shunt required a subsequent liver transplant and the EHPH
patient has not had any subsequent variceal hemorrhage and
is under consideration for a revisional shunt. Addressing
thrombosed shunts in the pediatric population has not
been well described. In some instances where thrombosis
has occurred, subsequent evaluation shows the patient to
be unshuntable and subsequent liver transplant and/or
radicalesophagogastrectomyaretheonlyoptions.Somehave
described a salvage shunt that can be performed such as a
mesocaval or mesogonadal shunt [20, 21]. However, these
salvageshuntshavebeenshowntobelessdurablethanifthey
were performed as the initial shunt of choice.
Some of our patients were candidates for liver transplan-
tation before PSSs. PSS has not precluded liver transplanta-
tioninourexperiencetodate.Althoughlivertransplantation
clearly has advantages over PSS because it fully addresses the
underlying liver disease when present, liver transplantation
is associated with the need for lifelong immunosuppression,
signiﬁcant mortality and morbidity, and other long-term
risks.
The eﬀects of PSSs and the development of PSE are still
disputed. It is diﬃcult to evaluate the eﬀect of PSS and
the development of PSE- related symptoms in the pediatric
population due to the lack of adequate control groups. In a
large prospective evaluation of PSSs in patients with EHPH,
Orloﬀ and colleaguesmade a thorough eﬀort to evaluate PSE
using the four-test index at each postoperative clinic visit. By
their assessment of 200 patients at long-term follow-up no
patient developed PSE [5]. In our series, screening for PSE-
related symptoms involved questions regarding scholastic
performance, fatigue, and perceived changes in memory.
Screening was conducted at post-operative visits or by
report from primary care providers near the patient’s home
(Table 2). In our study, 2 patients had EHPH, and at long-
term followup neither patient has developed any symptoms
related to PSE. Of interest, while patient number 2 did not
experience a rise in serum ammonia levels, patient number
1 experienced a doubling of his serum ammonia level
from 59 to 114µmol/liter. The reason this patient did not
develop any symptoms related to PSE despite the increase in
serum ammonia is likely due to the patient’s well-preserved
liver function pre- and postoperatively. Other studies have
suggested that PSE symptoms do occur in some EHPH and
IHPH patients who receive a PSS [2, 9]. Resolution of the
diﬀerence in observation might be made by the example
provided in our series. IHPH patients in our study were the
only patients to report any PSE- related symptoms despite
nonexistence of signiﬁcant change in serum ammonia levels.
It may be that patients with intrahepatic disease and or
injury, even those whose liver function appears normal by
traditional classiﬁcations, are still at higher risk for the devel-
opment of PSE because at some level their livers are not able
to cope with the changes created by the PSS. This appears to
be the case in our series where symptoms attributed to PSE
appeared to develop in 4 of 6 IHPH patients who were evalu-
ated for PSE at followup (Table 2). Again of note, each one of
theIHPHpatientswhodevelopedPSEdidnothaveanappre-
ciable increase in his serum ammonia levels postoperatively6 HPB Surgery
andpatientsnumber3and9didnothaveanysigniﬁcantliver
dysfunction before or after their shunt procedures.
Our series of patients is relatively small leading to what
we see as the biggest criticism in which many of the lessons
learned may be perceived as anecdotal. However, several
important issues are raised in our report that can contribute
to the overall discussion of PSSs in children. Our experience
with PSSs in the pediatric population supports what is
previously known in the literature in which patients with
good liver function will likely have long-term durable results
following their shunt procedures. Additionally, we provide
support for a spleen preserving procedure for hypersplenism
in thesetting ofIHPH.Most of thesepatients in the pediatric
population are likely to have a long-term life expectancy and
spleen-preservation should be obtained if possible. Patients,
who have HVOO, pose a signiﬁcant problem, as they will
likely have a rapid deterioration of liver function and require
immediate intervention. With regards to decompression,
it is diﬃcult to know whether TIPS or open PSS is best
for these patients. Both TIPSs and open PSSs have been
used as a short-term bridge to transplantation. However,
our experience has shown that some patients who receive a
surgical PSS may receive long-term decompression of their
outﬂow obstruction with a patent shunt and avoid the need
for transplantation. These long-term results appear to be
directly attributable to the increased durability of open PSSs
versus TIPSs. Finally, it appears from our series of patients
that PSE after shunting represents an ongoing problem, but
only in those patients with IHPH or liver injury regardless
of the measured liver function or serum ammonia levels.
Clearly these results raise the need for further studies into
the measured components of PSE.
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